ELISA/assay

ADMA (Asymmetric Dimethylarginine) ELISA

ADM31-K01

1 x 96 well

ADMA (Asymmetric Dimethylarginine) ELISA

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an “endogenous anti-atherogenic molecule” due to its diverse regulatory functions in vascular homeostasis. NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be down-regulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS. The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including patients with hyper­cholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular events and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

The competitive ADMA (Asymmetric Dimethylarginine) ELISA Kit uses the microtiter plate format. ADMA is bound to the solid phase of the microtiter plate. ADMA in the samples is acylated and competes with solid phase bound ADMA for a fixed number of rabbit anti-ADMA antiserum binding sites. When the system is in equilibrium, free Antigens and free Antigens-antiserum complexes are removed by washing. The antibody bound to the solid phase ADMA is detected by anti-rabbit/peroxidase. The substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase ADMA is inversely proportional to the ADMA concentration of the sample.

ELISA

Assay Kits

Oxidative Stress

1 x 96 well

ADMA

SDMA, Asymmetric Dimethylarginine, ADMA

0.03 umol/L

0.2 - 3.0 umol/L

20 uL

Serum, Plasma

3 hours

Human

RUO

Wet

2-8C